{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:44:48Z","timestamp":1791229488699,"version":"4.1.0"},"reference-count":44,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The treatment of chronic lymphocytic leukemia (CLL) has acquired new targeted therapies. In clinical trials, ibrutinib improved outcomes safely. Real-world data called for a reappraisal of ibrutinib strategies. We report on a single center\u2019s experience with ibrutinib monotherapy, aiming to explore the outcomes, tolerability, and prognosis of CLL patients in routine clinical practice. Materials and Methods: Data were collected from all CLL patients treated with ibrutinib at Fundeni Clinical Institute, Bucharest, Romania, between January 2016 and June 2021. Results: A total of one hundred twenty-three CLL adult patients were treated with ibrutinib. Of the patients, 87% had relapsed\/refractory CLL. The median age at ibrutinib initiation was 65 years; 44.7% of patients were staged Rai III\/IV. At 32-month median follow-up, the median progression-free survival (PFS) was 50 months, the overall survival (OS) was not reached, and the overall response rate (ORR) was 86.2%. The age or number of previous therapies did not impact outcomes or tolerability. An Eastern Cooperative Oncology Group performance status (ECOG PS) score \u2265 2 and shorter time from initiation of last therapy (TILT) before ibrutinib predicted inferior PFS. Baseline characteristics had no impact on the OS except for TILT in R\/R CLL patients. Drug-related adverse events (AEs) of any grade and grade \u2265 3 AEs were reported in 82.1% and 30.9% of the patients, respectively. Infections were the most common AEs (29.3%). Drug discontinuation was permanent in 43.9% of patients, mainly due to disease progression (17.1%) and toxicity (8.9%). Patients with a Cumulative Illness Rating Scale (CIRS) score \u2265 6 had a higher risk for toxicity-related discontinuation. An ECOG PS \u2265 2 predicted an increased rate of permanent discontinuation and grade \u2265 3 AEs. Conclusions: The outcomes of this study align with the results from ibrutinib clinical trials. Our study demonstrated that poor patient fitness, early relapse before ibrutinib, and permanent ibrutinib discontinuation are essential outcome determinants. Patient comorbidity burden and fitness were significant predictors for ibrutinib intolerance.<\/jats:p>","DOI":"10.3390\/medicina59020324","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T02:33:27Z","timestamp":1675996407000},"page":"324","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study"],"prefix":"10.3390","volume":"59","author":[{"given":"Ana-Maria","family":"Moldovianu","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Department of Hematology, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan","family":"Stoia","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Vasilica","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Ursuleac","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Department of Hematology, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorina Nicoleta","family":"Badelita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra Alina","family":"Tomescu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana Diana","family":"Preda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Bardas","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Cirstea","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Department of Hematology, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Department of Hematology, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","article-title":"Bruton\u2019s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement","volume":"191","author":"Petro","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton\u2019s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"Beuling","year":"2007","journal-title":"Immunity"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1093\/oncolo\/oyac114","article-title":"Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective","volume":"27","author":"Azoulay","year":"2022","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ajh.25261","article-title":"Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial","volume":"93","author":"Mato","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.3324\/haematol.2018.198820","article-title":"Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort","volume":"104","author":"Winqvist","year":"2019","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: A UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"Forum","year":"2016","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jha2.174","article-title":"Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK","volume":"2","author":"Hillmen","year":"2021","journal-title":"EJHaem"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/JBM.S202286","article-title":"Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: Results of a single-center retrospective analysis","volume":"10","author":"Nuttall","year":"2019","journal-title":"J. Blood Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-World Characteristics and Outcome of Patients Treated with Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Broccoli, A., Argnani, L., Morigi, A., Nanni, L., Casadei, B., Pellegrini, C., Stefoni, V., and Zinzani, P.L. (2021). Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245845"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1080\/10428194.2019.1620944","article-title":"Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece","volume":"60","author":"Dimou","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/ejh.13499","article-title":"Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"105","author":"Aarup","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"E95","DOI":"10.1002\/ajh.26437","article-title":"Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study","volume":"97","author":"Visentin","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1007\/s12325-021-01991-5","article-title":"Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status","volume":"39","author":"Huang","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ajh.25436","article-title":"Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis","volume":"94","author":"Byrd","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/asheducation-2010.1.481","article-title":"Understanding and managing ultra high-risk chronic lymphocytic leukemia","volume":"2010","author":"Stilgenbauer","year":"2010","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1182\/bloodadvances.2021004824","article-title":"Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?","volume":"5","author":"Tedeschi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood.2021012315","article-title":"Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and\/or TP53 mutations","volume":"138","author":"Sivina","year":"2021","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: A pooled analysis from four clinical trials","volume":"196","author":"Allan","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.15421","article-title":"Evaluation of 230 patients with relapsed\/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials","volume":"182","author":"Jones","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-136121","article-title":"Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study","volume":"136","author":"Huang","year":"2020","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.31554","article-title":"Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib","volume":"124","author":"Gordon","year":"2018","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1080\/10428194.2019.1602268","article-title":"Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice","volume":"60","author":"Hampel","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.14540","article-title":"Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: Results from a multi-centre study","volume":"181","author":"Mato","year":"2018","journal-title":"Br. J Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients with Chronic Lymphocytic Leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2021.280325","article-title":"Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study","volume":"107","author":"Innocenti","year":"2022","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of Major Bleeding with Ibrutinib","volume":"18","author":"Mock","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/324\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:28:48Z","timestamp":1760120928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["medicina59020324"],"URL":"https:\/\/doi.org\/10.3390\/medicina59020324","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}